WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL RESEARCH

Coden USA: WJPPCL

Review Article

2026

Volume: 03
Issue: 06

Page: 221-239

A REVIEW ON QUALITY BY DESIGN

Umesh* and Mrs. Kajal Mudgal

Mandsaur Institute of Pharmacy, Mandsaur University, Mandsaur.

Received: 30 April 2026 **Revised:** 12 May 2026 **Accepted:** 01 June 2026

Corresponding Author: Umesh

Address: Mandsaur Institute of Pharmacy, Mandsaur University, Mandsaur.

DOI: https://doi.org/10.5281/zenodo.20646694,

ABSTRACT

Quality by Design (QbD) is a strategic, risk-based approach to development and manufacturing that emphasizes building quality into a product from the very beginning, rather than testing for it after the product is finished. Historically used in the automotive and semiconductor industries, it has become the gold standard in pharmaceutical development.

KEYWORDS: Quality by design, Analytical target profile, Critical quality attributes, design of experiments. International Journal of Pharmaceutical Quality Assurance.

INTRODUCTION

In the modern pharmaceutical landscape, ensuring product quality is not merely a regulatory requirement but a scientific necessity. The traditional approach to pharmaceutical manufacturing involved post-production testing to ensure quality, commonly known as Quality by Testing (QbT). However, this approach often led to inefficiencies, increased costs, and risks of product recalls due to undetected variations in the production process.

To address these challenges, regulatory authorities and industry stakeholders have adopted a more scientific, risk- based, and proactive approach known as Quality by Design (QbD). QbD is defined by the International Conference on Harmonisation (ICH) as "a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management."

The concept of QbD integrates pharmaceutical science, analytical tools, engineering principles, and statistical design to ensure the consistent quality of pharmaceutical products.

Unlike conventional approaches, QbD is not reactive but proactive. It builds quality into the product from the very beginning by understanding the relationships between formulation components, process parameters, and critical quality attributes (CQAs).

Benefits of Quality by Design

The implementation of QbD offers several significant advantages:

- Enhanced product and process understanding
- Improved process capability and product quality
- Reduction in batch failures and product recalls
- Flexibility in regulatory post-approval changes
- Faster product development with data-driven decisions
- Increased confidence in regulatory submissions

Improved Product Quality

By embedding quality into the product design phase, QbD shifts the focus from reactive testing to proactive prevention of quality issues. This approach ensures:

- Reduced Variability: By understanding and controlling the critical quality attributes (CQAs) and critical process parameters (CPPs), manufacturers can minimize variability between batches. This means that every batch meets the pre-defined quality criteria reliably.

Reduced Costs and Waste

By optimizing processes and reducing variability, QbD minimizes waste and reduces production costs. This efficiency translates into cost savings for manufacturers and more competitive pricing for consumers.

Enhanced Regulatory Compliance

Regulatory agencies, such as the FDA and EMA, endorse QbD principles, as they provide a transparent, scientific approach to quality assurance. Implementing QbD helps organizations meet regulatory requirements more efficiently, reducing the risk of compliance issues.

In order to guarantee that the methods used for analysis are reliable, accurate, and effective, analytical method development is an essential component of the chemical and pharmaceutical industries. In this process, QbD has emerged as a crucial framework that offers a methodical approach to method development.[11-13]

The concept of QbD integrates pharmaceutical science, analytical tools, engineering principles, and statistical design to ensure the consistent quality of pharmaceutical.

Faster Time to Market

QbD's systematic approach accelerates product development by reducing the need for extensive testing and rework. This speed to market provides a competitive advantage, allowing companies to capture market share and respond to consumer demands quickly.

Continuous Improvement

Quality by Design (QbD), Continuous Improvement isn't just a corporate buzzword— it is the formal mechanism under the ICH Q10 guideline (Pharmaceutical Quality System) that allows you to optimize your manufacturing process over its entire lifecycle without constantly needing to file restrictive regulatory variations.

When you operate under a QbD framework, you establish a Design Space (the multidimensional combination of material attributes and process parameters that guarantee quality). As long as your improvements stay within this approved space, you can fine-tune your process in real-time based on actual manufacturing data.

Risk Mitigation

By identifying and managing risks early in the product lifecycle, QbD reduces the likelihood of failures and recalls. This risk mitigation not only protects the brand's reputation but also ensures the safety and satisfaction of consumers.[3-5]

Key Principles of QbD

Quality by design is based on several key principles that guide its implementation:

Gaining an understanding of the product and process

QbD necessitates a deep comprehension of the product as well as the procedures that go into producing it.

This involves identifying the desired quality attributes and the factors that can affect them.

Building quality into the product

The focus is on designing processes that inherently ensure quality, minimizing the need for extensive testing and quality checks after production.

Risk management

QbD involves identifying and managing risks throughout the product lifecycle. This proactive approach helps to anticipate and mitigate potential issues before they impact the product's quality.

Design of experiments (DoE)

Process optimization is made possible by investigating the connections between process factors and product qualities through structured experiments.

Continual improvement

To improve product quality and efficiency, QbD is a continual process that involves monitoring, assessing, and refining processes.[6,7]

Parts of Quality by Design

To guarantee its efficacy, Quality by Design is made up of a



Figure 1: Key principles of QbD.

Critical Quality Attributes (CQAs)

All data collected during commercial manufacturing shouldn't just be archived—it must be used to update your product knowledge base. As you gather data from different lots of raw materials, your understanding of how material attributes affect process behavior deepens.

Critical material attributes (CMAs) and critical process parameters (CPPs)

- CPPs, are aspects of the manufacturing process that have the potential to impact CQAs. These consist of elements, including mixing speed, pH, and temperature.
- Particle size and moisture content are examples of CMAs, which are characteristics of raw

materials that might affect the final product's quality.

The design area

Changes to the process parameters can be made inside the multidimensional Design Space without lowering the quality of the finished output. High levels of quality are consistently guaranteed when working in this profession.

Control strategy

A Control Strategy is a comprehensive plan to ensure consistent product quality by controlling raw materials, process parameters, and final product testing.

Key elements include:

- Raw material specifications: Testing and acceptance criteria for incoming materials.

Evaluation of risk

A key component of QbD is risk assessment, which entails locating and assessing possible hazards to quality. To rank hazards and create mitigation plans, tools like fishbone diagrams and FMEA are employed.

Advantages of Quality by Design (QbD)

QbD is a methodical and proactive approach to the development and production of pharmaceuticals. By integrating quality into product quality, cost savings.



Figure 2: Elements of QbD.

Improved Product Quality

By embedding quality into the product design phase, QbD shifts the focus from reactive testing to proactive prevention of quality issues. This approach ensures:

Reduced Variability: By understanding and controlling the critical quality attributes (CQAs) and critical process parameters (CPPs), manufacturers can minimize variability between batches. This means that every batch meets the pre- defined quality criteria reliably.

Better Predictability: Because product and process parameters are well characterized, performance is more predictable, reducing the chances of failure in the market.

Higher Patient Confidence: Consistent product quality enhances patient safety and therapeutic outcomes, leading to improved compliance and trust.

For example, in a tablet formulation, controlling the compression force and particle size distribution ensures that each tablet dissolves at the expected rate, providing consistent drug release.[6]

Better Control Over CQAs

Critical Quality Attributes are the physical, chemical, biological, or microbiological properties or characteristics that must be controlled to ensure product quality and patient safety.

Identification of CQAs involves understanding the product and its intended use. These attributes directly impact the performance of the drug and include:

- Assay and potency: Measures the amount of active pharmaceutical ingredient (API) in the formulation.
- Content uniformity: Ensures that each dosage unit contains the intended API amount within specified limits.
- Dissolution and release rate: Affects bioavailability and therapeutic effectiveness.
- Impurity levels and degradation products: Must be controlled to prevent toxicity.
- Physical attributes: Such as hardness, friability, particle size, and moisture content which influence stability and manufacturability.

Identifying CQAs helps focus control efforts on Resource efficiency

Focused experimentation and risk-based approaches ensure that resources are used effectively, maximizing return on investment.

Enhanced Regulatory Compliance

Regulatory agencies, such as the FDA and EMA, endorse QbD principles, as they provide a transparent, scientific approach to quality assurance. Implementing QbD helps organizations meet regulatory requirements more efficiently, reducing the risk of compliance issues.

Reduced risk of non-compliance

- *Proactive risk management*

QbD's emphasis on risk assessment and management reduces the likelihood of compliance issues, such as product recalls or quality defects.

- *Continuous monitoring*

Ongoing monitoring ensures that processes remain compliant with regulatory standards, minimizing the risk of deviations.

Risk Management and Mitigation

Proactive identification of risks

- *Early detection*

QbD involves early identification and assessment of risks throughout the product lifecycle, enabling proactive management of potential issues.

- *Prioritization of risks*

Tools like FMEA help prioritize risks based on their impact, guiding targeted mitigation strategies.

Enhanced process robustness

- *Robust processes*

Understanding the connection between process variables and product quality enables QbD to assist in the development of reliable, less variable processes.

- *Resilience to changes*

Robust processes can better withstand changes in raw materials, environmental conditions, or equipment, maintaining product quality.

Continuous Improvement and Innovation

Culture of continuous improvement

- *Data-driven decisions*

QbD fosters a culture of continuous improvement, where data- driven decisions lead to ongoing enhancements in product quality and process efficiency.

- *Feedback loops*

Continuous monitoring and feedback loops enable real-time adjustments, leading to iterative improvements.

Encouragement of innovation

- *Innovative solutions*

QbD encourages innovative solutions to quality challenges by promoting a deep understanding of processes and their interactions.

- *Adaptability*

The flexibility inherent in QbD allows companies to adapt quickly to new technologies or market demands, fostering innovation.

Patient-Centric Benefits

Improved patient safety and efficacy

- *Consistent product performance*

QbD ensures that products consistently meet quality standards, enhancing patient safety and therapeutic efficacy.

- *Fewer adverse events*

By minimizing variability and ensuring quality, QbD reduces the risk of adverse events related to product defects.

Enhanced patient confidence

- *Trust in quality*

When QbD concepts are used to product development, patients can feel more confident in the dependability and quality of the final product, which improves brand loyalty and reputation.

Environmental and Sustainability Benefits

Reduced environmental impact

- *Eficient resource use*

Optimized processes lead to more efficient use of resources, reducing waste and environmental impact.

- *Sustainability goals*

QbD aligns with sustainability goals by minimizing the carbon footprint and promoting responsible manufacturing practices.

Contribution to sustainable development

- *Long-term viability*

By focusing on quality and efficiency, QbD contributes to the long-term viability of manufacturing processes, supporting sustainable development initiatives.

Regulatory Aspects of QbD

Alignment with Global Regulatory Expectations

Key Regulatory Agencies and Guidelines

- ***U.S. Food and Drug Administration (FDA):***
- **Guidelines**: FDA has been a strong advocate for QbD, incorporating its principles into the Process Analytical Technology Guidance and ICH Q8(R2) Pharmaceutical Development guidelines.
- **Objective**: The FDA aims to enhance product quality through scientific understanding and risk management, encouraging the industry to adopt QbD.
- *European Medicines Agency (EMA):*
- **Guidelines**: EMA's Guideline on the Use of QbD in Drug Development promotes QbD principles to ensure robust and reliable pharmaceutical processes.
- **Objective**: EMA supports the use of QbD to achieve consistent product quality and regulatory compliance.
- *International council for Harmonisation (ICH):*
- **Guidelines**: The ICH has developed several guidelines that incorporate QbD, including:
- **ICH Q8(R2)**: Pharmaceutical development.
- **ICH Q9**: Quality risk management.
- **ICH Q10**: Pharmaceutical quality system.
- **Objective**: ICH guidelines aim to harmonize regulatory expectations across regions,

promoting a unified approach to pharmaceutical quality.

- *Importance of regulatory alignment*
- **Global Consistency**: Alignment with regulatory guidelines ensures that pharmaceutical products meet consistent quality standards worldwide, facilitating international market access.
- **Regulatory Compliance**: Compliance with QbD guidelines reduces the risk of regulatory issues, such as product recalls or penalties, enhancing brand reputation.

In order to guarantee that the methods used for analysis are reliable, accurate, and effective, analytical method development is an essential component of the chemical and pharmaceutical industries. In this process, QbD has emerged as a crucial framework that offers a methodical approach to method development.[11-13]

Role of QbD in Analytical Method Development: Analytical method development is the process of creating procedures to accurately measure compounds or properties. QbD in analytical method development involves designing methods that are reliable, reproducible, and suitable for their intended purpose.

Benefits of Using QbD in Analytical Method Development

Improved understanding of methods

QbD helps in understanding the relationship between method variables and method performance.

Enhanced method robustness

By understanding the method's critical variables, QbD enhances robustness and reliability.

Reduction of variability

Systematic experimentation under QbD reduces variability and increases consistency.

Eficiency in development

QbD can reduce the time and cost of method development by identifying optimal conditions faster.

Steps in QbD for Analytical Method Development Steps involved in implementing QbD in analytical method development:

1. ***Define the analytical target profile (ATP)***

The analytical target profile (ATP) outlines the requirements of the method. It includes: Purpose of the method: What is being measured, and why? Performance criteria: Accuracy, precision, sensitivity, specificity, etc.

2. ***Conduct risk assessment***

Risk assessment identifies potential variables that could affect the method's performance. Prioritizing risks can be done with the aid of instruments like failure mode and effects analysis (FMEA).

3. *Identify CQAs and critical method parameters (CMPs)* CQAs: Characteristics of the method that must be controlled to ensure quality (e.g., retention time, resolution). CMPs: Variables that can affect CQAs (e.g., pH, temperature, flow rate).

4. *DoE*

DoE is a structured approach to experimentation. It involves: Selecting variables: Based on the risk assessment, select variables to study.

- Creating an experimental matrix: Plan experiments systematically to explore interactions between variables.
- Analyzing data: Use statistical methods to determine the impact of variables on CQAs.

5. ***Develop and optimize the method***

Use insights from DoE to develop and optimize the method. Focus on:
- Robustness: Ensure the method performs consistently under different conditions.
- Accuracy and Precision: Validate the method's accuracy and precision.

6. ***Validate the Method***

Validation ensures that the method meets the ATP. Key validation parameters include:
- Linearity: The method should produce results that are directly proportional to the concentration of analytes.
- Accuracy: The closeness of measured values to the true value.
- Precision: Reproducibility of findings in the same circumstances.
- Specificity: Ability to measure analytes in the presence of other components.

- Sensitivity: Detection and quantification limits.

7. *Continuous monitoring and improvement* Once the method is validated and in use, continuous monitoring is essential. Collect data to ensure ongoing compliance with the ATP and make improvements as necessary.

Tools and Techniques in QbD for Analytical Method Development:

- *Statistical software*

Statistical software is vital for QbD, facilitating data analysis and DoE. Examples include: JMP: Offers powerful visualization and analysis tools. Minitab: Widely used for statistical analysis in various industries.

Design-Expert: Specializes in the design of experiments and optimization.

- *Risk assessment tools*

Fishbone Diagram: Identifies potential causes of variability. Failure mode and effects analysis: Risks are systematically assessed together with their effects using FMEA.

Risk ranking and filtering: Prioritizes risks based on severity and probability.

- *Process analytical technology (PAT)*

PAT involves using real-time data to monitor and control processes, ensuring compliance with quality standards.

Challenges and Considerations

Complexity and cost

Implementing QbD can be complex and costly initially, requiring investment in training and tools.

Regulatory requirements

Increasingly, regulatory bodies are expecting submissions to adhere to QbD standards, which calls for extensive documentation and rationale.

Change management

Transitioning to QbD requires a cultural shift within organizations, emphasizing proactive quality management.

Applications of QbD in analytical method development

QbD is a systematic approach that emphasizes understanding and controlling processes to ensure quality. In analytical method development, QbD offers a framework that enhances the robustness, accuracy, and efficiency of analytical methods. By applying QbD principles, organizations can develop methods that are better suited to their intended purposes, comply with regulatory expectations, and deliver consistent results.

Applications of QbD in Analytical Method Development

Chromatographic method development

Chromatography is a key analytical technique used in various industries, including pharmaceuticals, chemicals, and food. QbD enhances chromatographic method development by:

Optimizing separation conditions

Through DoE, QbD helps identify optimal conditions for separation, such as mobile phase composition, flow rate, temperature, and pH.

- *Enhancing robustness*

QbD guarantees that the procedure is reliable and consistent under various circumstances by comprehending the influence of variables on separation performance.

- *Improving resolution and sensitivity*

QbD aids in achieving better resolution and sensitivity, critical for detecting and quantifying analytes in complex matrices.

Spectroscopic Method Development

For both qualitative and quantitative analysis, spectroscopy is frequently used. QbD improves spectroscopic method development by:

- *Defining spectral parameters*

Identifying optimal wavelength, path length, and sample preparation methods to achieve accurate and precise measurements.

- *Managing interferences*

QbD helps understand and control potential interferences from matrix components, improving method specificity.

- *Enhancing calibration and validation*

QbD ensures that calibration models are robust and validated across a wide range of concentrations and conditions.

Assay development for biopharmaceuticals Biopharmaceuticals present unique analytical challenges due to their complexity and sensitivity. QbD aids in assay development by:

- *Defining critical attributes* Identifying key attributes such as potency, purity, and stability that must be monitored to ensure product quality.
- *Optimizing assay conditions*

Using DoE to evaluate variables such as enzyme concentration, reaction time, and temperature, leading to optimized assay conditions.

- *Ensuring method robustness*

By understanding the impact of environmental factors and matrix effects, QbD enhances the robustness of assays for biopharmaceuticals.



Figure 3: Applications of QbD.

Dissolution method development

Dissolution testing is critical for evaluating drug release and bioavailability. QbD improves dissolution method development by:

- *Identifying critical variables*

Determining key factors such as agitation speed, medium composition, and temperature that influence dissolution behavior.

- *Optimizing method conditions*

Using DoE to optimize dissolution parameters, ensuring consistent and reliable results.

- *Enhancing method transferability*

QbD ensures that dissolution methods are transferable across different laboratories and equipment, maintaining consistency.

Method Validation and Transfer

QbD supports method validation and transfer by:

- *Defining validation parameters*

Establishing clear criteria for accuracy, precision, linearity, specificity, and robustness.

- *Facilitating method transfer*

Ensuring that methods are transferable between laboratories and analysts through robust design and clear documentation.

- *Continuous monitoring*

Implementing monitoring systems to ensure ongoing method performance and compliance with specifications.[14,15]

CONCLUSION

Quality by Design (QbD) has emerged as a transformative approach in pharmaceutical development, fundamentally altering how drugs are designed, developed, and manufactured. Unlike traditional methods that rely heavily on empirical testing and end-product evaluation, QbD employs a scientific, systematic, and risk-based methodology. This approach ensures a deep understanding of the relationships between formulation components, process parameters, and the final product's critical quality attributes (CQAs). Such understanding allows for better control strategies, leading to products with enhanced quality, efficacy, and safety.

Implementing QbD leads to significant benefits including reduced development time and costs. Early identification of critical factors and optimized experimental designs prevent costly trial-and-error methods, minimizing batch failures and rework. Moreover, regulatory agencies around the world encourage QbD adoption, providing clear guidance and incentives. The regulatory flexibility gained by operating within an approved design space enables manufacturers to make certain changes without prior approval, expediting product lifecycle management and innovation. (99) Despite these advantages, challenges persist. The initial investment in technology, expertise, and training can be substantial, especially for small and medium enterprises Data management is another critical aspect, as QbD generates large, complex datasets requiring robust infrastructure and analytical skills. Furthermore, a cultural shift within organizations is essential to embrace the collaborative, knowledge-driven environment QbD demands. Overcoming resistance to change and ensuring continuous education are crucial for successful implementation.

Looking forward, advances in technology such as artificial intelligence, machine learning, and digital manufacturing promise to further enhance QbD's capabilities. Integration with Industry 4.0 tools and real-time analytics will improve process understanding and control, making pharmaceutical production more efficient and adaptable. Additionally, expanding QbD principles beyond pharmaceuticals into biotechnology, medical devices, and personalized medicine will broaden its impact on healthcare quality.

In conclusion, Quality by Design is more than just a regulatory expectation—it is a strategic approach that aligns product quality with patient safety and operational excellence. It equips the pharmaceutical industry to meet increasingly complex challenges while fostering innovation and maintaining high standards. The continued evolution and adoption of QbD will play a pivotal role in shaping the future of pharmaceutical development, ensuring that patients receive safe, effective, and high-quality medicines worldwide.

One of the major strengths of QbD is its focus on understanding the interplay between formulation variables, process parameters, and critical quality attributes (CQAs). This comprehensive knowledge base facilitates the

REFERENCES

1. ICH Q8(R2). Pharmaceutical Development. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2009.
2. ICH Q9. Quality Risk Management. International Council for Harmonisation, 2005.
3. ICH Q10. Pharmaceutical Quality System. International Council for Harmonisation, 2008.
4. Yu, L.X., Kopcha, M., & Yu, L. Pharmaceutical Quality by Design: Principles and Applications. Pharmaceutical Research, 2014; 31(4): 1087-1095.
5. Rathore, A.S., & Winkle, H. Quality by Design for Biopharmaceuticals. Nature Biotechnology, 2009; 27(1): 26-34.
6. Chowhan, Z.T., & Sinko, P.J. Pharmaceutical Quality by Design: A New Era in

Pharmaceutical Development. International Journal of Pharmaceutics, 2010; 399(1-2): 128-136.

7. FDA Guidance for Industry. (2006). Q8 Pharmaceutical Development.
8. FDA Guidance for Industry. (2006). Q9 Quality Risk Management.
9. FDA Guidance for Industry. (2008). Q10 Pharmaceutical Quality System.
10. Rathore, A.S. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharmaceutical Technology, 2011; 35(9): 74-83.
11. Bakeev, K.A. (2010). Process Analytical Technology: Spectroscopic Tools and Implementation Strategies for the Chemical and Pharmaceutical Industries. Wiley.
12. Jamal, S., & Al Shaikhi, F. Role of Quality by Design in Modern Pharmaceutical Product Development: A Review. Journal of Pharmaceutical Sciences, 2020; 109(1): 48-62.
13. Singh, S., & Mehta, S. Implementation of Quality by Design in Pharmaceutical Industry: A Review. International Journal of Pharmaceutical Sciences and Research, 2017; 8(5): 1966-1976.
14. Pluta, J., & Wrona, M. Quality by Design in the Pharmaceutical Industry: A Review. Drug Development and Industrial Pharmacy, 2019; 45(8): 1285-1294.
15. Prasad, S., & Sahoo, C. Quality by Design: A Tool for Quality Assurance in Pharmaceutical Industry. Asian Journal of Pharmaceutical and Clinical Research, 2019; 12(10): 32-37.
16. Kant, S., & Singh, A. Quality by Design: An Emerging Concept in Pharmaceutical Industry. International Journal of Pharmaceutical Sciences and Research, 2018; 9(3): 879-887.
17. ICH Q11. Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), 2012.
18. Rathore, A.S., & Winkle, H. Challenges and Opportunities in Applying QbD for Biopharmaceuticals. Bio Process International, 2012; 10(9): 26-32.
19. Hughes, M.T., & Yu, L.X. Advancing Pharmaceutical Quality by Design Through Regulatory Science. Journal of Pharmaceutical Sciences, 2015; 104(2): 276-283.
20. Rathore, A.S. Pharmaceutical Quality by Design: Implementation Challenges and Opportunities. Journal of Pharmaceutical Innovation, 2014; 9(2): 69-81.
21. De Luca, L., & Valsasina, L. Process Analytical Technology and Quality by Design Approaches: Synergies and Benefits. Journal of Pharmaceutical Sciences, 2019; 108(8): 2589-2598.
22. Rathore, A.S., & Winkle, H. Pharmaceutical Quality by Design: Biopharmaceutical

Applications. Nature Biotechnology, 2013; 31(12): 1152-1158.

23. Pathak, Y.V., & Prasad, M.R.N. Application of Quality by Design (QbD) in Pharmaceutical Formulations. International Journal of Pharmaceutical Sciences Review and Research, 2017; 44(1): 30-37.
24. Kumar, A., & Singh, S. Quality by Design (QbD) in Pharmaceutical Product Development. Journal of Drug Delivery and Therapeutics, 2016; 6(3): 35-42.
25. Das, A., & Nayak, S. Quality by Design Approach in Pharmaceutical Manufacturing. Asian Journal of Pharmaceutical Research and Development, 2018; 6(5): 21-28.
26. Shah, R.R. QbD and Its Application to Pharmaceutical Development. Drug Development Research, 2013; 74(8): 395-402.
27. Raju, N., & Maheshwari, R. Quality by Design: A Novel Approach in Pharmaceutical Manufacturing. International Journal of Pharmacy and Pharmaceutical Sciences, 2015; 7(4): 14-22.
28. Bhalekar, M.R., & Mahadik, K.R. Process Analytical Technology (PAT) and Quality by Design (QbD) in Pharmaceutical Development. Journal of Pharmaceutical Innovation, 2017; 12(2): 89-99.
29. Rathore, A.S., & Bhambure, R. Future of Quality by Design in Pharmaceutical Industry. Trends in Biotechnology, 2019; 37(9): 1004-1011.
30. FDA. (2011). Guidance for Industry: Process Validation: General Principles and Practices.
31. Bhosale RR, Osmani RA, Ghodake PP, Shaikh SM, Chavan SR. Nanoemulsion: A Review on novel profusion in advanced drug delivery. Indian J Pharm Biol Res., 2014; 2: 122-7.
32. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech., 2015; 5: 123-7.
33. Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm., 2008; 347: 136-43.
34. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm., 2007; 66: 227-43.
35. Yilmaz E, Borchert HH. Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema- an in vivo study. Int J Pharm., 2006; 307: 232-38.
36. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery ofaceclofenac. AAPS Pharm Sci Tech., 2007; 8(4): E104.

37. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Accelerated stability testing of celecoxib nano emulsion containing Cremophor-EL. Afr J Pharm Pharmacal., 2008; 2: 179.
38. Klang V, Matsko N, Zimmermann AM, Vojnikovic E, Valenta C. Enhancement of stability and skin permeation by sucrose stearate and cyclodextrins in progesterone nano emulsions. Int J Pharm., 2010; 393: 153-61.
39. Baspinar Y, Keck CM, Borchert HH. Development of a positively charged prednicarbate nano emulsion. Int J P.